MagForce AG
Max-Planck-Strasse 3
Haus 5.2
Berlin
12489
Germany
Tel: 49-30-3083800
Fax: 49-30-30838099
Website: http://www.magforce.de/
Email: info@magforce.com
94 articles about MagForce AG
-
Clinical Catch-Up: November 1-5
11/8/2021
The first week of November was marked by numerous clinical trial announcements. Here’s a look. -
MagForce AG: 'NanoTherm School' successfully enters its second round with Module B
12/11/2019
MagForce successfully hosted the second session of its practice-oriented, unique, multifaceted application training for the use of the NanoTherm therapy system in treating brain tumors
-
New hope for brain tumor patients in Saxony: Paracelsus Clinic Zwickau and MagForce AG open new NanoTherm therapy center for the East German region
12/5/2019
Use of innovative technology in the treatment of brain tumor patients, now also in Zwickau, the central treatment center in East Germany.
-
MagForce AG Publishes Financial Results for the First Half of 2019 and Operative Highlights
10/31/2019
Further German cooperation with the Paracelsus Clinic in Zwickau and first NanoTherm treatment center outside of Germany opened at the Independent Public Clinical Hospital No. 4 (SPKS4) in Lublin, Poland
-
MagForce AG to host Lunch Symposium on Local Therapies in Malignant Gliomas during the 19th European Congress of Neurosurgery (EANS2019)
9/25/2019
MagForce AG, a leading medical device company in the field of nanomedicine focused on oncology, is pleased to announce that it will host a scientific lunch symposium titled "Local Therapies in Malignant Gliomas - update and new perspectives" during the 19th European Congress of Neurosurgery in Dublin, Ireland.
-
MagForce AG: MagForce USA, Inc. Completed Enrollment and Treatment for Stage 1 and Prepares for Next Stage of its Pivotal, Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with NanoTherm Therapy
8/27/2019
Successful validation of standardized clinical procedure for instillation of nanoparticles in first patient cohort
-
MagForce AG successfully resolves and completes capital increase from authorized capital under exclusion of statutory subscription rights
6/25/2019
The Management Board of MagForce AG has resolved and successfully completed, with the approval of the Supervisory Board, on basis of the authorization provided for in the Company’s articles of association, an increase of the registerd share capital of the Company from currently EUR 26,463,802.00 to EUR 27,640,274.00 by issuing 1,176,472 new no-par value bearer shares under exclusion of the shareholders’ statutory subscription rights.
-
MagForce AG Publishes Financial Results for the Year 2018 and Operative Highlights
6/20/2019
MagForce AG, a leading medical device company in the field of nanomedicine focused on oncology, published today its financial results as of and for the year ended December 31, 2018 as well as operative highlights.
-
MagForce AG and the Paracelsus Clinic Zwickau announce cooperation agreement and the opening of a new NanoTherm treatment center
6/7/2019
With the treatment center at the Paracelsus Clinic in Zwickau another geographically important location will soon offer NanoTherm therapy for brain tumor patients
-
MagForce AG: Inauguration ceremony marks official opening of new NanoTherm Treatment Center at Independent Public Clinical Hospital No. 4 in Lublin, Poland
4/4/2019
Independent Public Clinical Hospital No. 4 in Lublin is the first hospital outside of Germany to offer NanoTherm Therapy for the treatment of brain tumor patients
-
MagForce AG successfully completes installation of mobile NanoTherm treatment center for brain tumors in Poland
3/21/2019
First hospital outside of Germany to offer MagForce’s NanoTherm therapy for the commercial treatment of brain tumor patients
-
MagForce AG: Newly launched ’NanoTherm® Therapy School’ kicks off with successful first training session
2/6/2019
MagForce introduces practice-oriented, unique, multifaceted application training for the use of NanoTherm Therapy in treating brain tumors
-
MagForce AG Publishes Financial Results for the First Half of 2018 and Operative Highlights
10/24/2018
Start of pivotal US prostate cancer study and treatment of first patients with NanoTherm therapy following U.S. FDA IDE approval in February and IRB approvals in April of this year
-
MagForce AG to host Lunch Symposium on Local Therapies for Malignant Gliomas at the 18th European Congress of Neurosurgery (EANS2018)
10/18/2018
MagForce AG is pleased to announce that it will host a scientific lunch symposium titled "Local Therapies for Malignant Gliomas" on Tuesday, October 23, 2018 at the 18th European Congress of Neurosurgery in Brussels, Belgium.
-
MagForce AG to participate in nine upcoming international conferences in H2 2018
9/10/2018
MagForce AG today announced its participation in nine upcoming scientific and investor conferences in the second half of 2018
-
MagForce AG announces positive results of 2018 Annual General Meeting
8/9/2018
MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, held its Annual General Meeting in Berlin today.
-
MagForce AG announces successful capital increase of the subsidiary MagForce USA, Inc.
8/8/2018
MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced the successful completion of a capital increase of its subsidiary MagForce USA, Inc.
-
MagForce AG to host Lunch Symposium about Local Therapies for Malignant Gliomas at the 2018 meeting of the German Society of Neurosurgery (DGNC)
6/5/2018
MagForce AG is pleased to announce that it will host a scientific lunch symposium titled “Local Therapies for Malignant Gliomas” at the 69th Annual Meeting of the German Society of Neurosurgery (DGNC).
-
MagForce USA Receives FDA Investigational Device Exemption Approval to Conduct a Clinical Trial With NanoTherm Therapy as Focal Ablation Treatment for Intermediate Risk Prostate Cancer
2/12/2018
MagForce anticipates to initiate patient enrollment in this study in the coming months.
-
MagForce AG to Participate at SNO 2017 Annual Meeting From November 16-19 in San Francisco, USA
11/14/2017
MagForce AG today announced its participation in the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology, SNO 2017, held from November 16-19, 2017, in San Francisco, California, USA.